Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT00051688. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.
Study identification
- NCT ID
- NCT00051688
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2003
- Primary completion
- Not listed
- Completion
- Jul 31, 2004
- Last update posted
- Jul 10, 2006
2003 – 2004
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ACRC/Arizona Clinical Research Center | Tucson | Arizona | 85712 | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Comprehensive Cancer Centers of the Desert | Palm Springs | California | 92262 | — |
| Cancer Institute Medical Group | Santa Monica | California | 90404 | — |
| Georgetown University Medical Center, Lombardi Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | 33612-9497 | — |
| Northwestern University Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| Kansas City Oncology and Hematology Group | Kansas City | Missouri | 64111 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00051688, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 10, 2006 · Synced Sep 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00051688 live on ClinicalTrials.gov.